Post

New research · Neurology
Neurology · 1d
Meta-analysisNeurology · 2026

Exploring Between-Study Heterogeneity in Extended-Window IV Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis of 18 Randomized Controlled Trials.

Mohamed F Doheim, Abdullah M Al-Qudah, Romil Singh … Raul G Nogueira
Read paper
NeurologyMeta-analysis

Extended-window IV thrombolysis improves excellent functional recovery in acute ischemic stroke.

Exploring Between-Study Heterogeneity in Extended-Window IV Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis of 18 Randomized Controlled Trials.

Mohamed F Doheim et al. · Neurology · 2026
Background

IV thrombolysis (IVT) is the standard-of-care evidence-based treatment of eligible patients with acute ischemic stroke (AIS) within 4.5 hours of symptom onset.

Methods

We searched MEDLINE, Cochrane Library, and ClinicalTrials.gov from inception through February 2026.

n = 5,168 patients
Results

extended clot-busting treatment led to a 21% higher chance of excellent recovery from stroke

RR by subgroup · 95% CI
null = 1
ntly improved excellent functional
1.21
good functional outcome
1.09
sICH
1.90
but did not increase 90-day mortality
1.04
More results

Of the 18 included RCTs, 11 required advanced perfusion imaging (CTP or MRP mismatch) or diffusion-weighted imaging/fluid-attenuated inversion recovery mismatch to confirm salvageable tissue; the remaining 7 permitted noncontrast CT/CT angiography-based selection.

More results

IVT was associated with significantly greater odds of reduced disability across the full mRS spectrum (common OR 1.18; 95% CI 1.07-1.32; p = 0.004).

IVT increased the risk of sICH (3.2% vs 1.4%; RR 1.90; 95% CI 1.28-2.84; p = 0.002; number needed to harm = 57) but did not increase 90-day mortality (13.7% vs 13.0% RR 1.04; 95% CI 0.92-1.18; p = 0.53).

“
Conclusion

CLASSIFICATION OF EVIDENCE: This study provides American Academy of Neurology Class I evidence that IVT administered 4.5-24 hours after moderate-to-severe AIS onset in patients with salvageable tissue, where thrombectomy is not readily available, improves functional outcome at 90 days without increasing mortality.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
17.8 years
Patients with congenital myasthenic syndromes waited 17.8 years for a diagnosis.
Guideline
“The introduction of the first anti-amyloid mAb represents a paradigm shift in the management of AD, but is not free of challenges.”
Study
more than 3.4 billion people
the global count of people living with brain and nerve conditions
Cohort Study
27.3%
the highest proportion of patients diagnosed with Charcot-Marie-Tooth disease type 1A
Study
95%
most specialized training program leaders were open to a unified date for job offers
Study
over 80 cases
documented cases of brain and nerve conditions found in Inquisition records
Guideline
12-14 years
the age when patients with nerve and muscle conditions should start moving to adult care
Cohort Study
71.8%
children with D/EE-SWAS achieved freedom from seizures after taking ethosuximide